PL3689913T3 - Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii - Google Patents

Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii

Info

Publication number
PL3689913T3
PL3689913T3 PL19210918T PL19210918T PL3689913T3 PL 3689913 T3 PL3689913 T3 PL 3689913T3 PL 19210918 T PL19210918 T PL 19210918T PL 19210918 T PL19210918 T PL 19210918T PL 3689913 T3 PL3689913 T3 PL 3689913T3
Authority
PL
Poland
Prior art keywords
pcsk9 inhibitor
treat hyperlipidemia
hyperlipidemia
treat
pcsk9
Prior art date
Application number
PL19210918T
Other languages
English (en)
Inventor
Marie BACCARA-DINET
Laurence BESSAC
Umesh CHAUDHARI
Corinne Hanotin
Robert C. Pordy
William J. Sasiela
Daniel A. Schwemmer Gipe
Original Assignee
Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology
Publication of PL3689913T3 publication Critical patent/PL3689913T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
PL19210918T 2013-10-11 2014-10-10 Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii PL3689913T3 (pl)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09
EP19210918.9A EP3689913B1 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia
EP14802527.3A EP3055333B1 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Publications (1)

Publication Number Publication Date
PL3689913T3 true PL3689913T3 (pl) 2022-07-04

Family

ID=52813751

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14802527T PL3055333T4 (pl) 2013-10-11 2014-10-10 Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii
PL19210918T PL3689913T3 (pl) 2013-10-11 2014-10-10 Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14802527T PL3055333T4 (pl) 2013-10-11 2014-10-10 Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii

Country Status (14)

Country Link
US (1) US20150140002A1 (pl)
EP (2) EP3689913B1 (pl)
JP (2) JP6846931B2 (pl)
KR (3) KR20160062166A (pl)
CN (3) CN115192704A (pl)
AU (2) AU2014331754B2 (pl)
CA (1) CA2926942A1 (pl)
EA (1) EA037526B1 (pl)
ES (1) ES2914978T3 (pl)
IL (1) IL244995B (pl)
MX (3) MX2016004580A (pl)
PL (2) PL3055333T4 (pl)
TW (1) TWI669131B (pl)
WO (1) WO2015054619A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN103476796A (zh) 2011-01-28 2013-12-25 赛诺菲 治疗特定受试者组的方法中使用的针对pcsk9的人抗体
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP3536712B1 (en) 2011-09-16 2023-05-31 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EA201592267A1 (ru) 2013-06-07 2016-04-29 Ридженерон Фармасьютикалз, Инк. Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
AU2014348765A1 (en) 2013-11-12 2016-06-09 Regeneron Pharmaceuticals, Inc. Dosing regimens for use with PCSK9 inhibitors
WO2016010927A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
JP2017528427A (ja) 2014-07-16 2017-09-28 サノフィ・バイオテクノロジー ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
JP2018516624A (ja) * 2015-04-15 2018-06-28 コンシーヴァルブ エルエルシー 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
MX2019012083A (es) 2017-04-13 2019-11-21 Cadila Healthcare Ltd Nueva vacuna de peptidos contra la pcsk9.
WO2018200489A1 (en) 2017-04-25 2018-11-01 The Brigham And Women’S Hospital, Inc. Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
CN109963877B (zh) * 2017-06-14 2023-01-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
JP7426940B2 (ja) * 2018-03-06 2024-02-02 サノフィ・バイオテクノロジー 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
CN115066272A (zh) * 2019-12-10 2022-09-16 再生元制药公司 Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN103476796A (zh) * 2011-01-28 2013-12-25 赛诺菲 治疗特定受试者组的方法中使用的针对pcsk9的人抗体
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP3536712B1 (en) * 2011-09-16 2023-05-31 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
AU2020203636B2 (en) 2023-05-18
JP2019214594A (ja) 2019-12-19
CA2926942A1 (en) 2015-04-16
WO2015054619A8 (en) 2016-03-31
CN105814085A (zh) 2016-07-27
MX2020004023A (es) 2020-08-13
CN115192704A (zh) 2022-10-18
JP6846931B2 (ja) 2021-03-24
KR20230119045A (ko) 2023-08-14
TWI669131B (zh) 2019-08-21
TW201605475A (zh) 2016-02-16
AU2020203636A1 (en) 2020-06-25
JP2016538248A (ja) 2016-12-08
AU2014331754B2 (en) 2020-06-18
PL3055333T4 (pl) 2020-07-27
KR20160062166A (ko) 2016-06-01
IL244995A0 (en) 2016-05-31
MX2022013172A (es) 2022-11-30
EA201690754A1 (ru) 2016-10-31
KR20220048051A (ko) 2022-04-19
JP6994484B2 (ja) 2022-02-04
EA037526B1 (ru) 2021-04-08
PL3055333T3 (pl) 2020-06-01
ES2914978T3 (es) 2022-06-20
EP3055333A2 (en) 2016-08-17
EP3055333B1 (en) 2019-12-04
CN115154599A (zh) 2022-10-11
WO2015054619A3 (en) 2015-06-04
AU2014331754A1 (en) 2016-05-26
MX2016004580A (es) 2016-12-08
WO2015054619A2 (en) 2015-04-16
US20150140002A1 (en) 2015-05-21
EP3689913B1 (en) 2022-03-23
IL244995B (en) 2019-12-31
EP3689913A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
IL244995A0 (en) Using pcsk9 inhibitor to treat hyperlipidemia
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
RS63939B1 (sr) Inhibitori lizin specifične demetilaze-1
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
PL3293176T3 (pl) Sposób wytwarzania inhibitora PDE4
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
EP2962186A4 (en) PROVISION OF CODE CHANGE JOB PACKAGES OF VARIOUS SIZE FOR VALIDATORS
EP2958964A4 (en) TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
EP3632467C0 (en) INHIBITORS OF COMPLEMENT FACTOR H
HK1221645A1 (zh) 的苯並喹啉抑制劑
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
ZA201409181B (en) Treatment of waste water
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
PT3055333T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
PT3689913T (pt) Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
ZA201409002B (en) Treatment of waste water
GB201308117D0 (en) Inhibitor of calcifying disorders
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors